UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: May 4, 2004
Tapestry Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
| 0-243201 |
| 84-1187753 |
(State of |
| (Commission |
| IRS Employer |
|
|
|
|
|
|
| 4840 Pearl East Circle, Suite 300W |
|
|
(Address of principal executive offices and Zip Code) | ||||
| ||||
(303) 516-8500 | ||||
(Registrant’s telephone number, including area code) | ||||
NaPro BioTherapeutics, Inc.
(Former name, if changed since last report)
Item 5. Other Events.
On May 4, 2004, the Company changed its corporate name to Tapestry Pharmaceuticals, Inc. from NaPro BioTherapeutics, Inc. Tapestry’s common stock will trade on the Nasdaq SmallCap Market under the symbol “TPPH” effective May 5, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TAPESTRY PHARMACEUTICALS, INC. | |
|
| |
|
| |
May 4, 2004 | By: | /s/ Gordon Link |
|
| Gordon Link |
|
| Senior Vice President, |
|
| Chief Financial Officer |
|
| (Principal Financial Officer) |
|
|
|
3